[go: up one dir, main page]

MX2018000240A - Metodos para tratar el vhc. - Google Patents

Metodos para tratar el vhc.

Info

Publication number
MX2018000240A
MX2018000240A MX2018000240A MX2018000240A MX2018000240A MX 2018000240 A MX2018000240 A MX 2018000240A MX 2018000240 A MX2018000240 A MX 2018000240A MX 2018000240 A MX2018000240 A MX 2018000240A MX 2018000240 A MX2018000240 A MX 2018000240A
Authority
MX
Mexico
Prior art keywords
treatment
methods
weeks
compound
pharmaceutically acceptable
Prior art date
Application number
MX2018000240A
Other languages
English (en)
Other versions
MX389088B (es
Inventor
Campbell Andrew
M Awni Walid
Liu Wei
M Bernstein Barry
J Podsadecki Thomas
Dutta Sandeep
M Menon Rajeev
Wang Tianli
Mensing Sven
Lin Chih-Wei
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018000240A publication Critical patent/MX2018000240A/es
Publication of MX389088B publication Critical patent/MX389088B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/21—Design, administration or maintenance of databases
    • G06F16/215—Improving data quality; Data cleansing, e.g. de-duplication, removing invalid entries or correcting typographical errors
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/23—Updating
    • G06F16/2365—Ensuring data consistency and integrity
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/23—Updating
    • G06F16/2379—Updates performed during online database operations; commit processing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F7/00—Methods or arrangements for processing data by operating upon the order or content of the data handled
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/25—Integrating or interfacing systems involving database management systems
    • G06F16/252—Integrating or interfacing systems involving database management systems between a Database Management System and a front-end application

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Databases & Information Systems (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Data Mining & Analysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Computer Security & Cryptography (AREA)
  • Quality & Reliability (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención presenta terapias exentas de interferón para el tratamiento del VHC. Preferiblemente, el tratamiento es a lo largo de una duración más corta de tratamiento, tal como no más de 12 semanas. En un aspecto, el tratamiento comprende la administración de al menos dos agentes antivíricos de acción directa a un sujeto con infección por el VHC, en donde el tratamiento dura 12 semanas y no incluye la administración de interferón o de ribavirina, y dichos al menos dos agentes antivíricos de acción directa comprenden (a) Compuesto 1 o una de sus sales farmacéuticamente aceptables y (b) el Compuesto 2 o una de sus sales farmacéuticamente aceptables.
MX2018000240A 2015-07-08 2016-07-07 Métodos para tratar el vhc. MX389088B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190045P 2015-07-08 2015-07-08
US201562266954P 2015-12-14 2015-12-14
PCT/US2016/041334 WO2017007934A1 (en) 2015-07-08 2016-07-07 Methods for treating hcv

Publications (2)

Publication Number Publication Date
MX2018000240A true MX2018000240A (es) 2018-03-14
MX389088B MX389088B (es) 2025-03-20

Family

ID=56497883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000240A MX389088B (es) 2015-07-08 2016-07-07 Métodos para tratar el vhc.

Country Status (10)

Country Link
US (2) US20180177779A1 (es)
EP (1) EP3319604A1 (es)
JP (2) JP6808660B2 (es)
CN (1) CN107921038A (es)
AU (1) AU2016291154B2 (es)
BR (1) BR112018000383A2 (es)
CA (1) CA2991417A1 (es)
HK (1) HK1255481A1 (es)
MX (1) MX389088B (es)
WO (1) WO2017007934A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN110302361A (zh) 2014-04-02 2019-10-08 艾伯维公司 治疗hcv的方法
US20170248953A1 (en) * 2016-02-25 2017-08-31 Ford Global Technologies, Llc Autonomous peril control
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CA3120686A1 (en) 2018-11-20 2020-05-28 Abbvie Inc. Methods for treating acute hcv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
EP2897611B1 (en) * 2012-09-18 2019-07-24 AbbVie Inc. Methods for treating hepatitis c
EP2897612A1 (en) * 2012-09-18 2015-07-29 AbbVie Inc. Methods for treating hepatitis c
SI3213750T1 (sl) * 2013-03-14 2020-11-30 Abbvie Inc. Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C
CA2925328A1 (en) * 2013-10-25 2015-04-30 Abbvie, Inc. Methods for treating hcv
CN110302361A (zh) * 2014-04-02 2019-10-08 艾伯维公司 治疗hcv的方法

Also Published As

Publication number Publication date
BR112018000383A2 (pt) 2018-09-18
US20180177779A1 (en) 2018-06-28
JP6808660B2 (ja) 2021-01-06
JP2018519321A (ja) 2018-07-19
AU2016291154A1 (en) 2018-01-25
CA2991417A1 (en) 2017-01-12
HK1255481A1 (zh) 2019-08-16
AU2016291154B2 (en) 2021-10-21
MX389088B (es) 2025-03-20
US20240232171A1 (en) 2024-07-11
EP3319604A1 (en) 2018-05-16
CN107921038A (zh) 2018-04-17
JP2021050223A (ja) 2021-04-01
WO2017007934A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX388482B (es) Métodos para tratar el virus de la hepatitis c.
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12018550148A1 (en) Hepatitis b antiviral agents
PH12018550150B1 (en) Elimination of hepatitis b virus with antiviral agents
MX2018000240A (es) Metodos para tratar el vhc.
PH12014500833A1 (en) Methods for treating hcv
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
AU2019384793A8 (en) Methods for treating acute HCV
MX2018000213A (es) Metodos para tratar el vhc.
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
EA201892004A1 (ru) Противовирусные средства для лечения гепатита b
UA101772U (uk) Спосіб лікування хронічного вірусного гепатиту с із супутньою неалкогольною жировою хворобою печінки
ES2572355A2 (es) Combinacion de aad para uso en el tratamiento del vhc